Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer

• Main Authors: Amy Kwan (Author), Faith Howard (Author), Natalie Winder (Author), Emer Atkinson (Author), Ameera Jailani (Author), Priya B. Patel (Author), Richard Allen (Author), Penelope D. Ottewell (Author), Gary C. Shaw (Author), Joe Conner (Author), Caroline Wilson (Author), Sanjay K. Srivastava (Author), Sarah J. Danson (Author), Claire Lewis (Author), Janet E. Brown (Author), Munitta Muthana (Author)
• Format: Book
• Published: MDPI AG, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Oncolytic viruses (OV) promote anti-tumour responses through the initiation of immunogenic cancer cell death which activates the host's systemic anti-tumour immunity. We have previously shown that intravenously administered HSV1716 is an effective treatment for mammary cancer. However, intraven...